Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC

Affiliations

Comment

David Killock. Nat Rev Clin Oncol. 2023 Mar.

. 2023 Mar;20(3):137.

doi: 10.1038/s41571-023-00737-2.

No abstract available

Comment on

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, Hirata K, Akazawa N, Kataoka K, Sharma S, Aushev VN, Aleshin A, Misumi T, Taniguchi H, Takemasa I, Kato T, Mori M, Yoshino T. Kotani D, et al. Nat Med. 2023 Jan;29(1):127-134. doi: 10.1038/s41591-022-02115-4. Epub 2023 Jan 16. Nat Med. 2023. PMID: 36646802 Free PMC article.

1. Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. https://doi.org/10.1038/s41591-022-02115-4 (2023) - DOI - PubMed - PMC